Usual and unusual antibacterial effects of quinolones
- PMID: 2175306
- DOI: 10.1093/jac/26.suppl_b.7
Usual and unusual antibacterial effects of quinolones
Abstract
Recently documented antibacterial effects of quinolones are reviewed. DNA gyrase is most likely to be the primary target site for these agents. Quinolones rapidly kill susceptible bacteria; the mechanisms of the bactericidal activity, still poorly understood, probably involve new protein synthesis. Quinolones alter membrane integrity before cell death, leading to leakage of cytoplasmic constituents. In Gram-negative bacteria, quinolones act as chelating agents for outer membrane divalent cations, disorganizing the bacterial lipopolysaccharide layer and facilitating the further entry of quinolone molecules in a 'self-promoted' pathway. Quinolones inhibit plasmid replication and reduce the efficacy of plasmid conjugation. Subinhibitory concentrations of quinolones can interfere with bacterial virulence factors, such as bacterial adherence to the host cell, phagocytosis and production of enzymes implicated in virulence. Recent studies also indicate synergism of quinolones with oxacillin against methicillin-resistant staphylococci and describe improved activity of newer compounds against Gram-positive pathogens.
Similar articles
-
Quinolone uptake by bacteria and bacterial killing.Rev Infect Dis. 1989 Jul-Aug;11 Suppl 5:S941-6. doi: 10.1093/clinids/11.supplement_5.s941. Rev Infect Dis. 1989. PMID: 2549609 Review.
-
Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance.Clin Infect Dis. 1998 Aug;27 Suppl 1:S54-63. doi: 10.1086/514923. Clin Infect Dis. 1998. PMID: 9710672 Review.
-
Mode of action of the new quinolones: new data.Eur J Clin Microbiol Infect Dis. 1991 Apr;10(4):223-31. doi: 10.1007/BF01966994. Eur J Clin Microbiol Infect Dis. 1991. PMID: 1650698 Review.
-
Type II topoisomerases as targets for quinolone antibacterials: turning Dr. Jekyll into Mr. Hyde.Curr Pharm Des. 2001 Mar;7(5):337-53. doi: 10.2174/1381612013398013. Curr Pharm Des. 2001. PMID: 11254893 Review.
-
[The history of the development and changes of quinolone antibacterial agents].Yakushigaku Zasshi. 2003;38(2):161-79. Yakushigaku Zasshi. 2003. PMID: 15143768 Japanese.
Cited by
-
Lomefloxacin clinical pharmacokinetics.Clin Pharmacokinet. 1993 Jul;25(1):6-19. doi: 10.2165/00003088-199325010-00002. Clin Pharmacokinet. 1993. PMID: 8394795 Review.
-
Ecological implications of an improved direct viable count method for aquatic bacteria.Appl Environ Microbiol. 1997 Sep;63(9):3643-7. doi: 10.1128/aem.63.9.3643-3647.1997. Appl Environ Microbiol. 1997. PMID: 16535694 Free PMC article.
-
Absorption interactions with fluoroquinolones. 1995 update.Drug Saf. 1995 May;12(5):314-33. doi: 10.2165/00002018-199512050-00004. Drug Saf. 1995. PMID: 7669261 Review.
-
Relative beta-lactamase- and transpeptidase-inhibitory activities of the new quinolone WIN-57273 in Staphylococcus aureus.Antimicrob Agents Chemother. 1992 Apr;36(4):894-7. doi: 10.1128/AAC.36.4.894. Antimicrob Agents Chemother. 1992. PMID: 1323958 Free PMC article.
-
Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.Drugs. 1991 Dec;42(6):1018-60. doi: 10.2165/00003495-199142060-00009. Drugs. 1991. PMID: 1724637 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources